— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.